Abstract
Abstract
Background
Subclinical hyperthyroidism (SCH) is found to be associated with renal dysfunction. Hyperthyroidism is a well-known cause of secondary systolic hypertension. However, the effect of SCH on the kidney and its vasculature is still unknown.
Aim
To assess the presence of renal function changes and renal vasodysfunction in SCH patients and their relation to hypertension.
Methods
The study included 321 patients with SCH and 80 healthy matched controls. Laboratory investigations included thyroid function tests, anti-TSH receptor antibody (TRAb), creatinine, estimated glomerular filtration rate (eGFR), serum osmolarity (S. Osmol), urine osmolarity (U. Osmol), Fractional Excretion of Sodium (FeNa), Fractional Excretion of Potassium (FeK), copeptin (CPP), and aldosterone/renin ratio (ARR). Ultrasound for the thyroid gland, echocardiography, total peripheral resistance (TPR), flow-mediated dilatation (FMD), and Renal Arterial distensibility (RAD) was also done.
Results
Serum creatinine was significantly lower while eGFR was significantly higher in SCH patients compared to euthyroid subjects (mean 0.59 ± 0.11 mg/dl Vs mean 0.8 ± 0.1 mg/dl, p = 0.001 and mean 128.28 ± 14.69 ml/min/1.73m2 Vs mean 100.49 ± 14.9 ml/min/1.73m2, p = 0.013, respectively). The TPR and FMD showed a significant decrease in SCH group compared to controls (mean 975.85 ± 159.33 mmHg.min/L Vs mean 1120.24 ± 135.15 mmHg.min/L, p = 0.045 and mean 7.03 ± 4.02% Vs mean 13.48 ± 4.57%, p = 0.003, respectively). RAD was significantly higher in hypertensive SCH patients compared to normotensive SCH patients (mean 17.82 ± 2.46 mmHg Vs mean 11.98 ± 3.21 mmHg, p = 0.001).
Conclusion
SCH patients showed vascular resistance reduction. Alterations in thyroid hormones and blood pressure could be the driving mechanisms for the change in renal functions in patients with SCH.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference43 articles.
1. H.T. El-Zawawy, A.A. El-Aghoury, E.Z. Azzam, A.A. Deghady, M.A. Abdellatif, Osteopontin as a marker in thyroid disease: Relation to body mass index. Endocrine and Metabolic. Science 10, 100049 (2020)
2. S. De Leo, S.Y. Lee, L.E. Braverman, Hyperthyroidism. Lancet 388(10047), 906–918 (2016)
3. T.P. Links, T. van der Boom, W.T. Zandee, J.D. Lefrandt, Cardiovascular effects of overt and subclinical hyperthyroidism: focus on differentiated thyroid cancer. Endocr. Connect. 10(1), R43–R51 (2021)
4. E. Berta, I. Lengyel, S. Halmi, M. Zrínyi, A. Erdei, M. Harangi, D. Páll, E.V. Nagy, M. Bodor, Hypertension in thyroid disorders. Front. Endocrino. 10, 482 (2019)
5. J.S. Neves, C. Vale, M. von Hafe, M. Borges-Canha, A.R. Leite, J. Almeida-Coelho, A. Lourenço, I. Falcão-Pires, D. Carvalho, A. Leite-Moreira. Thyroid hormones and modulation of diastolic function: a promising target for heart failure with preserved ejection fraction. Ther. Adv. Endocrinol. Metab.11 (2020). https://doi.org/10.1177/2042018820958331.